Overview

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a phase I / II, multi-center, single-arm, open-label study to evaluate the safety and efficacy of ALMB-0168 in patients with osteosarcoma whose prior standard treatment have failed.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AlaMab Therapeutics (Shanghai) Inc.
Collaborator:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.